ELAB Elevai Labs Inc.
374
$0.6601
$0.0049
(0.74%)
| Watchers | 374 |
| 52-Wk Low | $0.5709 |
| 52-Wk High | $4.24 |
| Volume | 27,481.00 |
| 52-Wk High | $4.24 |
| 52-Wk Low | $0.5709 |
Elevai Labs reports Q4 revenue $698,591 vs. $554,654 in Q3The Fly • about 2 months ago
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
Share to Feed
Elevai Labs reports Q4 results...
Company reports record annual revenues of $1.71 Million for 2023, up 123.5% over the previous year Company reports record Q4 2023 revenues of $698,591, up 403% from Q4 2022 NEWPORT BEACH, Calif...
In this piece, we will take a look at the 15 best beauty stocks to invest in. If you want to skip our overview of the global beauty industry, then you can take a look at the 5 Best Beauty Stocks To...
ELEVAI Physician-Dispensed Skincare Now Available Direct to Consumers
Purchase and Provider Journey
Elevai e-commerce portal webview of the shopping cart and physician finder tool...
ELEVAI LABS announces issuance of patent...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
Utility Patent Covers the formulation for ELEVAI's flagship exosome-based skin care productsNEWPORT BEACH, Calif., Jan. 24, 2024 (GLOBE NEWSWIRE) -- ELEVAI LABS, INC., (NASDAQ: ELAB) a medical...
NEWPORT BEACH, Calif., Jan. 17, 2024 (GLOBE NEWSWIRE) -- ELEVAI LABS, INC., (NASDAQ: ELAB) a medical aesthetic company specializing in physician-dispensed skincare, today announced certain...
ELEVAI Labs to commercialize use of proprietary technology designed to produce high-quality, cGMP grade mesenchymal stromal cells at lower-costNEWPORT BEACH, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE...